Phase 2 Study of Lisaftoclax and Pirtobrutinib in Relapsed Mantle Cell Lymphoma
A phase 2 study is underway to assess the efficacy and safety of lisaftoclax combined with pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma after BTK-targeted therapy.
Phase II
mantle cell lymphoma therapies
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing phase 2 study of lisaftoclax and pirtobrutinib represents a significant development in the treatment landscape for relapsed mantle cell lymphoma, particularly for patients who have not responded to BTK inhibitors. Success in this trial could reshape treatment guidelines and enhance competitive positioning for companies in the oncology sector.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor enrollment progress and initial efficacy results from the trial, as well as any safety concerns that may arise.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.